Amgen faces compounding safety crisis on two continents.

At least 20 deaths and 22 cases of potentially fatal liver injuries in Japan have been linked to an Amgen rare disease drug, prompting partner Kissei Pharmaceutical to halt new prescriptions. U.S. regulators had already asked Amgen to voluntarily withdraw the drug before the Japan data emerged, meaning AMGN now faces effective commercial shutdown in two major markets simultaneously. Shares fell nearly 3%, and the combination of fatality data, liver injury cases, and dual-market regulatory pressure raises serious questions about liability exposure and how much of the drug's revenue was already baked into long-term forecasts.

Legacy automakers absorb brutal EV transition costs with no clear payoff.

Stellantis dropped 4.53% after announcing a €1 billion EV joint venture with China's Dongfeng Group while simultaneously participating in a wave of 20,000-plus U.S. salaried job cuts, a combination that signals financial strain rather than strategic confidence. Honda reported its first operating loss in nearly 70 years, a 414.3 billion yen deficit driven by EV headwinds in the U.S., though Citi and Nomura held their buy ratings on HMC. DexCom offered a sharp contrast, surging 6.61% after its investor day laid out at least 10% annual revenue growth through 2030 and a board governance agreement with activist Elliott Investment Management, showing that concrete roadmaps and accountability structures can rebuild market trust even in uncertain environments.

DLocal sells off despite a 73% volume surge.

DLocal beat Q1 2026 earnings estimates and reported total payment volume up 73% year-over-year, but shares fell 13.03% as investors focused on net take rate compression driven by pricing pressure from large enterprise clients. A hiring freeze announced alongside results signaled that management is shifting to defense, which markets read as a structural problem rather than a temporary one. Gemini Space Station moved in the opposite direction, jumping 6.08% after Q1 results beat on both revenue and loss metrics and the company secured a $100 million strategic investment from Winklevoss Capital Fund, illustrating how a high-profile capital injection can override thin fundamentals for early-stage names.